14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $227.75 $262.51 Friday, 3rd May 2024 UTHR stock ended at $262.40. This is 1.65% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.57% from a day low at $255.93 to a day high of $262.51.
90 days $208.62 $262.51
52 weeks $204.44 $262.51

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Jul 18, 2023 $235.70 $238.49 $235.38 $237.91 240 948
Jul 17, 2023 $232.00 $236.99 $231.23 $234.26 286 921
Jul 14, 2023 $230.64 $233.32 $229.93 $232.00 263 203
Jul 13, 2023 $230.57 $234.39 $229.36 $229.81 304 909
Jul 12, 2023 $223.99 $232.47 $223.50 $229.91 436 734
Jul 11, 2023 $223.81 $223.90 $219.86 $221.65 240 901
Jul 10, 2023 $211.58 $223.85 $211.58 $223.14 718 494
Jul 07, 2023 $213.00 $214.16 $211.26 $211.82 311 637
Jul 06, 2023 $219.07 $219.34 $212.58 $213.00 350 311
Jul 05, 2023 $223.07 $223.74 $218.72 $219.43 326 143
Jul 03, 2023 $220.24 $224.95 $220.24 $223.75 186 601
Jun 30, 2023 $220.97 $222.63 $218.87 $220.75 274 368
Jun 29, 2023 $214.80 $220.48 $214.72 $219.79 410 067
Jun 28, 2023 $215.00 $215.00 $212.00 $214.80 190 026
Jun 27, 2023 $219.88 $219.88 $214.87 $215.12 324 576
Jun 26, 2023 $222.46 $222.54 $218.44 $220.78 192 325
Jun 23, 2023 $225.29 $225.30 $222.19 $222.36 303 060
Jun 22, 2023 $223.24 $226.26 $221.86 $225.23 230 074
Jun 21, 2023 $223.40 $224.02 $221.38 $223.07 378 019
Jun 20, 2023 $228.20 $228.20 $222.69 $223.40 533 814
Jun 16, 2023 $230.00 $232.42 $230.00 $230.26 542 866
Jun 15, 2023 $227.56 $229.85 $227.00 $229.59 229 231
Jun 14, 2023 $228.76 $230.63 $225.46 $226.28 299 098
Jun 13, 2023 $226.43 $231.25 $225.32 $229.53 255 113
Jun 12, 2023 $230.00 $230.00 $224.35 $227.90 242 575
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT